-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HtqIaHZ/+dS+AUmG/KstJuvZ5cjPlElsVrMs4dT4TRGIRCh1OcwHKz+PaLpMrbmX
 +xnDIeehM0iykT2cU8i2sg==

<SEC-DOCUMENT>0001119774-07-000012.txt : 20070208
<SEC-HEADER>0001119774-07-000012.hdr.sgml : 20070208
<ACCEPTANCE-DATETIME>20070208073813
ACCESSION NUMBER:		0001119774-07-000012
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070208
FILED AS OF DATE:		20070208
DATE AS OF CHANGE:		20070208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		07590145

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		STREET 2:		TEL AVIV
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sixkfebruary82007.htm
<DESCRIPTION>6-K - FEBRUARY 8, 2007
<TEXT>
<html>
<head>
<meta name=Generator content="Microsoft Word 11 (filtered)">
<title>6-kFebruary82007</title>

<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Miriam;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h1
	{margin-top:3.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	text-align:center;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h2
	{margin-top:3.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h4
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h5
	{margin-right:0cm;
	margin-left:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h6
	{margin:0cm;
	margin-bottom:.0001pt;
	line-height:150%;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	text-decoration:underline;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin:0cm;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0cm;
	margin-bottom:.0001pt;
	line-height:150%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:right;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-indent:27.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-align:justify;
	text-indent:27.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0cm;
	margin-right:2.9pt;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	text-indent:30.95pt;
	line-height:16.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:#000066;
	background:white;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0cm;
	margin-bottom:.0001pt;
	background:navy;
	font-size:10.0pt;
	font-family:Tahoma;}
p
	{margin-right:0cm;
	margin-left:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:Tahoma;}
span.tdfont1
	{font-family:Verdana;
	color:#484848;
	font-weight:normal;}
span.bold1
	{color:#34344C;
	font-weight:bold;}
span.contenttext1
	{font-family:Verdana;
	color:#333333;
	font-weight:normal;
	text-decoration:none none;}
p.ind1, li.ind1, div.ind1
	{margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-align:justify;
	text-indent:1.0cm;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.centhead, li.centhead, div.centhead
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:12.0pt;
	margin-left:0cm;
	text-align:center;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.small, li.small, div.small
	{margin-right:0cm;
	margin-left:0cm;
	font-size:9.0pt;
	font-family:Tahoma;
	color:#555555;}
span.defaultlrg1
	{font-family:Arial;
	color:black;
	font-weight:normal;
	text-decoration:none none;}
p.headeredgarbold, li.headeredgarbold, div.headeredgarbold
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.Headingnum1, li.Headingnum1, div.Headingnum1
	{margin-top:3.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:22.7pt;
	text-align:center;
	text-indent:-22.7pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.Headingnum2, li.Headingnum2, div.Headingnum2
	{margin-top:3.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:45.35pt;
	text-indent:-22.65pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.Headingnum3, li.Headingnum3, div.Headingnum3
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:68.05pt;
	text-indent:-25.5pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman";}
p.Headingnum4, li.Headingnum4, div.Headingnum4
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:90.7pt;
	text-indent:-19.8pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.Indent0, li.Indent0, div.Indent0
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:14.4pt;
	margin-bottom:.0001pt;
	text-indent:-14.4pt;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Indent1, li.Indent1, div.Indent1
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:14.4pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Indent2, li.Indent2, div.Indent2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:28.8pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Indent3, li.Indent3, div.Indent3
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:57.6pt;
	margin-bottom:.0001pt;
	text-indent:-14.4pt;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tableheading, li.Tableheading, div.Tableheading
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.Tablewith1underline, li.Tablewith1underline, div.Tablewith1underline
	{margin-top:0cm;
	margin-right:2.85pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tablewith1underline0, li.Tablewith1underline0, div.Tablewith1underline0
	{margin-top:0cm;
	margin-right:-1.4pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tablewithdoubleline, li.Tablewithdoubleline, div.Tablewithdoubleline
	{margin-top:0cm;
	margin-right:2.85pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tablewithdoubleline0, li.Tablewithdoubleline0, div.Tablewithdoubleline0
	{margin-top:0cm;
	margin-right:-1.4pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tbalewithoutstyle, li.Tbalewithoutstyle, div.Tbalewithoutstyle
	{margin-top:0cm;
	margin-right:2.85pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tablewithoutstyle, li.Tablewithoutstyle, div.Tablewithoutstyle
	{margin-top:0cm;
	margin-right:-1.4pt;
	margin-bottom:0cm;
	margin-left:0.1pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Index, li.Index, div.Index
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
@page Section1
	{size:612.0pt 792.0pt;
	margin:35.95pt 90.0pt 72.0pt 90.0pt;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
- -->

</head>
<body lang=EN-US link="#000066" vlink=purple>
<div class=Section1>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>FORM 6-K</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>SECURITIES AND EXCHANGE COMMISSION</b></p>
<h3 Style="text-align:center;margin-top:12.0pt;  margin-bottom:3.0pt; margin-left:0cm; page-break-after:avoid; font-size:14.0pt;  font-weight:normal;font-family:"Times New Roman"" ><b style='font-size:11.0pt'>Washington</b><b style='font-size:11.0pt'>, D.C. 20549</b></h3>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Report
of Foreign Private Issuer</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;</b></p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Pursuant to rule 13a-16 or 15d-16 of the Securities
Exchange Act of 1934</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">for the month of February 2007</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><u style='font-size:11.0pt'>Compugen Ltd.</u></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Translation of registrant's name in English)</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><u style='font-size:11.0pt'>72 Pinchas Rosen Street, Tel-Aviv 69512, Israel</u></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Address of principal executive offices)</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F.</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Form 20-F&nbsp;&nbsp;<u> X&nbsp;&nbsp;</u>             Form
40-F&nbsp;___</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">On February 8, 2007 Compugen Ltd. (the
&quot;Registrant&quot;) issued a Press Release, filed as Exhibit 1 to this
Report on Form 6-K, which is hereby incorporated by reference herein.</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b>&nbsp;</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b><u style='font-size:11.0pt'>SIGNATURE</u></b></p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.</p>
<p  Style="margin:0cm;margin-left:1.0cm;margin-right:1.0cm;margin-top:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-left:288.0pt;margin-right:1.0cm;margin-top:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">                                    </p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Compugen Ltd.</p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Registrant)</p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">By:    <u>/s/ Nurit Benjamini</u></p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Title:  Chief Financial Officer</p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Date: February
8, 2007</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p Style="margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p Style="margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<b style='font-size:11.0pt;font-family:"Times New Roman"'><P Style="font-size:10.0pt;font-family:"Times New Roman"" align=center><B>__1__</B>&nbsp;</P><br clear=all
style='page-break-before:always'>
</b>
<p Style="margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;</b></p>
<p Style="margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>Exhibit 1</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><img width=257
height=136 src="image001.jpg">                          </p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:14.0pt'>Compugen to Present Experimental Data for</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:14.0pt'>its Novel Splice Variant of c-Met Receptor</b></p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b><i style='font-size:11.0pt'>Data to be presented at GTCBio`s Cancer Drugs Research
&amp; Development Conference</i></b></p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt; color:black;font-family:Verdana"> </p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Tel
Aviv, Israel - February 8, 2007 - Compugen Ltd. (NASDAQ: CGEN) announced today that it will present
experimental results for its previously disclosed CGEN-241 therapeutic
candidate, a splice variant of c-Met receptor, at GTCBio`s Cancer Drugs
Research &amp; Development Conference (February 8-9, 2007, Philadelphia, PA).<!-- Created Using Viltech Software --></p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">CGEN-241
is a truncated form of the c-Met receptor predicted by Compugen's discovery
engine to be encoded by a splice variant and to be secreted from the cell. It
comprises part of the extracellular domain and ends in a stretch of unique
amino acids. In the assessment of the biological activity of CGEN-241 as an
antagonist of the HGF-Met pathway in various assays and model systems, the
molecule demonstrated strong inhibition of multiple cellular functions related
to this pathway, including cell proliferation, motility and invasion. These
findings indicate that CGEN-241 is a potent antagonist of the HGF/Met pathway,
with anti-tumorigenic and anti-metastatic activities, suggesting a therapeutic
potential. </p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">The
protein product of the c-Met oncogene is the tyrosine kinase receptor for
hepatocyte growth factor (HGF), and Compugen has discovered soluble variants of
this receptor. The HGF-Met pathway is involved in a wide range of biological
functions, including cell proliferation and survival, cell migration and
invasion, as well as angiogenesis. Inappropriate activation of this signaling
pathway has been implicated in tumor development and progression of solid
tumors and hematologic malignancies. In view of the critical role that this
pathway plays in cancer, various inhibitory strategies have been employed by
companies to therapeutically target the pathway and several candidates are
currently in development. </p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>About
Compugen</b></p>
<p style='margin:0cm;font-size:11.0pt;margin-bottom:.0001pt;text-align:justify'>Compugen`s mission is to be the world leader in the
discovery and licensing of product candidates to the drug and diagnostic
industry. The Company`s powerful discovery engines enable the predictive
discovery of numerous potential therapeutics and diagnostic biomarkers. This
capability results from the Company`s decade-long pioneering efforts in the
deeper understanding of important biological phenomena at the molecular level
through the incorporation of ideas and methods from mathematics, computer
science and physics into biology, chemistry and medicine. To date, Compugen`s
diagnostic and therapeutic product discovery efforts and its initial discovery
engines have focused mainly within the areas of cancer, immune-related and
cardiovascular diseases. The Company's primary commercialization pathway for
its therapeutic and diagnostic product candidates is to enter into milestone
and revenue sharing out-licensing and joint development agreements with leading
companies. Compugen has established an agricultural biotechnology affiliate -
Evogene, and a small-molecule drug discovery affiliate - Keddem Bioscience. For
additional information, please visit Compugen's corporate Website at
www.cgen.com. </p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b><i style='font-size:
11.0pt'>Company contact:</i></b></p>
<h1 Style="margin-top:3.0pt; margin-bottom:3.0pt; margin-left:0cm; text-align:justify; page-break-after:avoid; font-size:11.0pt; font-weight:normal;font-family:"Times New Roman"" >Naomi
Rabbie</h1>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Corporate
Communications Manager</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Compugen
Ltd.</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Email:
naomir@cgen.com<!-- Created Using Viltech Software --></p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Tel:
+972-52-598-9894</p>
<P Style="font-size:10.0pt;font-family:"Times New Roman"" align=center><B>__2__</B>&nbsp;</P></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image001.jpg
<DESCRIPTION>COMPUGEN LOGO
<TEXT>
begin 644 image001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#__@`<4V]F='=A<F4Z($UI8W)O<V]F="!/
M9F9I8V7_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-#AT5%A$8(Q\E)"(?(B$F
M*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_VP!#`0H+"PX-#AP0$!P[
M*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SO_P``1"`"(`0$#`2(``A$!`Q$!_\0`'``!``,!`0$!`0``````
M``````4&!P0#"`$"_\0`21```00!`@(%!0P%"@<``````0`"`P0%!A$2(0<3
M,4%1%")A<8$5%C)65Y&2E*'1TN$C,U*3TQ<E0E-B9G*DL<%4@J*RPN+P_\0`
M&0$!`0$!`0$```````````````$"`P0%_\0`+!$!``(!`@0$!04!````````
M``$"$0,$$B$QT4%1H?`3%&&QP3)QD;+A\O_=``0`*/_:``P#`0`"$0,1`#\`
MV9$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1
M$!$1`7X2&@DG8#F2O":[6@)9)9@CD`^"^0!5N6?4CY7.CU)@HV$^:SJ2>$>&
M_'S6ZUR.J?7.$@F?$77'EAV+HZ<KFGU$-YK^/?\`8/\`9O\`U"7\*Y>MU/\`
M&C!?5S^->5F]J&G7?8L:KP+(HQNYWDY.P]CUUBE/<_XCO]_V#_9O_4)?PK^9
M.D##L;O'7R<SB0`QE"3<_.`%4;NLK%RJZ#W\T:X=VR08V5KP/0>>RMFB\->J
M5SD+VH+>5%A@,'6%[6-8>>_"X]I]*U;3I2,VCW_`LL$AF@9*Z)\1>T'@?MQ-
M]!V[UZ(B\JB(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("X,M?MT*[9
M*>,FR$CG;=7$]K=AXDN*[U7=4P5XFLOW-09'%0-`C/DKO,))/,^:>?<M4C-L
M"%LUVW+#[-KHV?--(=WR22PN<X^LE>7N=5^3`?3A^]>/NCI_Y0<Q](_PT]T=
M/_*#F/I'^&O9BWE_9'J<?4:"3T8M`':3)`/]U"6:&9=9D=4T)@XX.+]&V01N
M<!Z2'C<KMR%K3-K'SPSZVR]R-S#O7+_UG?P\V=ZIVVC?^#S_`-.+[EUTXGWG
M\RBU8O$YFSE:L-W1^"BK/E`E>V-A+6]^VSSS6K-:&M#6@``;`#N6$8Z]I/%Y
M*O?K4\]UU>02,XG1;$CN/+L6RX+/4=0XYMVB\[=CXW#9T;O`A>?<UMRGP]_6
M5A)HB+R*_]#9D1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0%^$;]J_4
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M<2T/`Y@;@'O7>JCT>5IZ^,M=?@6X7BFY0@O/'YH\[SB?5[%;E\[4B*VF(:$1
M%@$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`7G-/%7B=+/*R*-HW<][@T
M#UDJ-RMS.PRAF*Q,%IO]*2:T(Q[``2HN>SJVS'U=C3.+E9OOPR7>(?,6+<4S
MS_,#VR6J,+;INAI:LH4I7$?IA(QY`]`)V4+[HL^4^O\`NH%V]3J'XFX3ZR/P
M*-FSLE>9T,^&TM'(P[.8[(,!:?`^8O16L=(_"/7W19\I]?\`=0+ARFI8<7$U
MYZ0I;;G'81U*<,CO6>X?.HZ]D<W:L%]:[I.E'W1QRPN^<N!W7E7&JK<[8*N5
MT[/,[X,<?D[G'V!B[12.LX].R(G(9+`Y2X^W=U'FY)G[;N%9C1R[.0?L%UX'
M3V+U)<\EQN7SCR.;Y75VAD8])X_L5TP.EM1OE$N>NT8XFG]17IPES_6[@Y#U
M*Z05H*S"RO#'$TG<B-H:"?8LWW$5C%??HN'/B,7!AL7!CZY<YD+=N)YW<X]Y
M/I)7:B+PS.9S*B(B@(B("(B`B(@(B("(B#__T=F1$0$1$!$1`1$0$1$!4C/9
M3"9.YP7(-0@UR6`58IF,)WYGS>WUJ[JHVI,W%;E8=9XJ#9YVBDK,XF#N!W?X
M+KI=??807#I?^HU7_F?O3ATO_4:K_P`S]ZF/*,U\>L/]69^-/*,U\>L/]69^
M->C/U]9[(K.4EQD,<?N5AM37G.)#Q+8LQ!H^W=07DM/Y/\E]9F_`K!JM\H=7
MGR6O&C?=C!CX#MX^<&/^TJ-PE&/.Y2*A2UOE)97[N+>IE;YHYGF7\EWI.*Y[
MHZ]-:4HY^X63:0LX^M'^LFGNR@^IK2T;E:3A-.8G3T!BQM-D/%\)YYO=ZW'F
M5W5J\=.K'7C+N")H:"]Q<=AXD]JRK5G2E>DNRT\"]L%>,EILEH<Z0]Y;OR`^
MU>;.IKVQ7HO1K:+"<AF=<85M2S?RER$6V=9"'2`[CEVM[NT<BK_HS71R>FKM
M[,O8U^-VZV5@V#VD<CMX]VWJ6;[:U:\43DRNZ+%,OTE:BS-T08ISJ44C^&**
M%H=(_<[#<GO]2X9]4:TP&2=7N9.W'8CV+HIR'C8C<<N86XVEYZS&3+>45'BU
MQ+>Z-KF<:&P786F$\(W`EY`$;_X@50:6OM7S7H(F9":RYTC0(6Q,WDY_!Y-[
MUBFVO;/T,MV18)E-;:M?DI>OR-BG+&\M->/S!&1W;?>I#(Z_U;8P--_GU(7;
ML==C9L;#AX'NV'AZ5OY2_+G!EM:+*.C75N:O:B]S+]R2Y!+$YP,O-S".>^_A
MW*)S_2#J%FH+[*.4=%59.YD3!&P@-!V[QZ%GY6_'-<F6VHL-R6KM;G%4[-BS
M8JU901%.Q@89CXDC\AR5HZ,]99+)W+&,RM@V0R$S1S/'G``@$$]_:EMM:M>+
M)EI2+"+G2+J=]R=\&5?'"9'&-@B9YK=^0[/!6G6.J<YA,#@88<@YE^Q!UMF3
M@:2[D.6VVPYD_,D[6\3$9ZF6G(LNT#JW,7K.1NYO)ODH4*O6/!8T#<GEV`=P
M*KN:Z1M0Y>Z[R*U)1KEVT4,')VW=N>TE(VMYM-?(RW-%AUW6.M\,R/'7K4U:
M=OZ0.EC:9'-/8"2#N.1]*M.@M5Y*QCLME\_D72TZ36@;L:.?,G;8#<]@]JEM
MM:M>+,&6D(L7N](&J-2Y5M+#%U1LS^&&&$#C/^)Q]'AL%QV-3ZTTQEW5KV2F
M,\6Q=%,X2L<"-Q_\%J-I?IF,^1ENB+/M5ZVM1Z&QF4QLIJV<@\=@#N$`'B',
M>(V52P^NM9V;Q97FER+Q&XB$0M([/A'8`[#M6:[:]J\1EMR+Y^&N]4LM>4^[
M-@N!WX#MP>KAVVV6[XVR^[BZEN1H8^>%DCFCN)`*SJZ%M+&2)=2(BX**MZ@Q
MD/E+;$&D:F8EFWZV1[HV.:1MMOQ#G^2LB\;=<6ZLM=TDD0D:6\<3^%[?2#W%
M:K;AG(I?D$GR9TOW\'W)Y!)\F=+]_!]REO>8WXPY[Z]^2>\QOQASWU[\EW^)
M7S^_=$%>QN0DIR,Q_1[0JV2!P2O?`]K>?>W;FO?05?)LR-M^2HXBN6QAK#1;
M%Q[[\P>`D[<AVJ6]YK?C#GOKWY+TP&C<;IR_9O4YK4DUINTKIY`[BY[[]@Y[
MJSJ5X)COW'3JN:6OI3*2P;]8VJ_;;M')?/\`BX8I\K3AG>UD+YV->YQV`:7#
M??V+Z5DC9+&Z.1H>QX+7-(W!![0L]R'0]C9[#I*.1GJ1N._5.8)`WT`[@[+6
MVUJ4B8L3#^=6:\T]7RWD,N$@S`KM`$W$PM:3VM&X/H49JB[!=Z-H[V/PS,5#
M<NM#V1@?I&M#MG'8#EN/L4SC.B'$5)FR7KD]UK3N(MA&P^O;F?G5SO8BAD<6
M_&6:S'5',#.K`V#0.S;;LV[DG4TJ37AYX&&Z#DI0ZQI3Y">."&+B?QR.V:'!
MIVY^M<^L,M'FM4WK\+N*%S^&)WBUHV!]NV_M5]L=#5-TI-;,3QQD\FR1->1[
M=PI7!]%V$Q-AEFR^7(31G=O7`!@/CPCM]NZ]$[C2BW'GGA,2I&5K38/HPH4I
MVF.;)VS9<P\B&`<M_P#I*\NC"HV?5S;4@_1TH'S.)[N7"/\`5:5JO1%?5EBO
M+9O3UQ786M9&&D'<\SS]07A@^CZG@:N1AKW[#WWX>I,CFMWC'/LV'I^Q<OF*
M_#F/&5PQ7(VW7\C:N/YNGE?(?:25;]>_S=@=-X,<C#5ZZ0?VG;?[\2LL70[B
MXY6/.4MN#7`\):S8[=W8I34G1W4U+ECD+&1LPGJVQMCC:WA:!ZQZ5TG<:<VK
MSY0F%)Z,FBD,WG'CS:5,AI/B=S_X_:J*29'%SSS<=R?6M6U'@ZNA^CR_3JV)
M)G9"=C"^0`'GMRY=VS3\ZH.DL/'GM34\=,'&&0DR\)V/"`2>:ZZ=XGBU/#L+
M#TB9W&W*.(Q.)LQV(:<7$]T9W:#PAK1Z]M_G7+HR*6CA-0Y[A(9!3->-WB]^
MW9ZN7SJT,Z&J0L<3\Q8=!O\``$30[;PXOR5S][6+;IU^!CK]72?&6%K3SY_T
MM_'?GNO/;7TZTBE>9A\]TF0ONUV6'B.$RM$CSV-;N-S\RL72%FZN;U,9*,PE
MJUX6PQO;V';<G;VG[%<(.ANBRR'3Y>Q+`#OU;8PUQ'AQ?DNBUT08FQ:DEBOV
M:['NW;$QK>%@\!N%UG<:4VBV3$J?3KRU.B?(6V`CRV]'&XC]AO\`[*$TM8HU
M-3X^SD9!'5AF#WN()`V&XY#T[+4,_/BM#:2IX2UCY<G2L<<;B7!I)WXMSZ>?
M+;P5"QS]!S6WNNP9:M$UO$UAF$@<?V?-;O\`:KIWXJVG$XD<^N,[#J'4\]RJ
MXNK-:V*(D;;@=^WI)*E+5>6AT0U"T$"_?ZR0^(`(;_V@JK]2[+9DPXZKPFS,
M1!`S^B">0]@[UO?O9H3Z6AP%R/K:\<+(R0=CQ`?"![COS4UKUTHI!#$-,85F
M<R,E=^5BQG5Q%XED.V_,#8<QW%=$N)T]U[F.U6^5X=P\3:$CN(]G([\U=)>A
MBJZ0]5FIFQ[\FO@:XCV[C_13FGNC3"X*TRY(Z6]9C.['3;!K#XAH[_7NI;<T
MZQ;T,,_U_$,7#A,`R4R-HU"]SBWAW<\^'=V+KZ/_`.;=.ZCSAY&*OU,9_M$$
M_P"O"KEJ'HVIZBS,V3L9.S&^4-'`QK=F@#;EN%[PZ`IP:2GT['>L-BL3=;)-
MPMXSS'+LVVY!<YUZ?#BN?W_)AB5"JZ]?K5&\W3RMC'M("^EHHVPQ,B8-FL:&
MM'@`J3A^BS'8C+ULBW(69G5G\;6/:W8GN[`KRN6YU:ZDQPK$"(B\BB(B#__2
MV9$1`1$0$1$!$1`1$0$1$!$1!&YG`8W4$$<&3KF>.-W&UO&YNQVVWY%<N)T;
M@<'=\LQU'J9^$LX^L<[D>WM*G$6HO:(QGD"(BR"(B#DR6,HY>FZID*T=B!QW
M+'CO\1X%5EW17I5S^(5K#1^R+#ME<46ZZEZ_ID1&&TMA<`2[&T(X9"-C*=W/
M(_Q'FI=$69F9G,@B(H"(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(
5B`B(@(B("(B`B(@(B("(B`B(@__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
